Real Estate & Construction » Real Estate | Panacea Global Inc.

Panacea Global Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2009
2010
2011
2012
2013
Cash & Short Term Investments
1,098.90
-
328.70
109.20
2,309.60
Total Accounts Receivable
3.50
-
-
-
40.60
Other Current Assets
-
-
51.40
73.20
8.50
Total Current Assets
1,102.30
-
380.10
182.40
2,358.60
Net Property, Plant & Equipment
380.60
-
49.60
89.40
78.20
Total Investments and Advances
-
-
915.80
912.60
911.70
Long-Term Note Receivable
899.40
-
-
-
-
Intangible Assets
-
50,000.00
50,000.00
50,000.00
50,000.00
Total Assets
2,382.30
50,000.00
51,345.50
51,184.30
53,348.50
ST Debt & Current Portion LT Debt
44.40
-
-
-
-
Accounts Payable
32.70
-
146.90
1,236.90
390.10
Other Current Liabilities
0.00
2,566.40
3,412.10
2,562.50
2,294.40
Total Current Liabilities
77.10
2,566.40
3,559.00
3,799.40
2,684.50
Other Liabilities
204.00
-
-
-
-
Total Liabilities
281.10
2,566.40
3,559.00
3,799.40
2,684.50
Common Equity (Total)
2,101.20
47,433.60
47,786.40
47,384.90
50,664.00
Total Shareholders' Equity
2,101.20
47,433.60
47,786.40
47,384.90
50,664.00
Total Equity
2,101.20
47,433.60
47,786.40
47,384.90
50,664.00
Liabilities & Shareholders' Equity
2,382.30
50,000.00
51,345.50
51,184.30
53,348.50

About Panacea Global

View Profile
Address
330 Highway 7 East
Richmond Hill Ontario L4B 3P8
Canada
Employees -
Website -
Updated 09/14/2018
Panacea Global, Inc. is a biotechnology company focused on the discovering, developing and commercializing of diagnostic products for the management of cancer. The company provides blood, serum and tissue tests to diagnose and monitor cancer through a licensing agreement with Panacea Pharmaceuticals. Its current product line allows for accurate detection of the most common forms of cancer, which includes diagnostic tests for lung, breast, prostate and colon cancers.